Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
1998-09-08
2002-11-05
Budens, Robert D. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S325000, C435S352000, C435S353000, C435S354000, C435S358000, C435S361000, C435S004000, C435S366000, C435S372000, C435S372300
Reexamination Certificate
active
06475718
ABSTRACT:
BACKGROUND OF THE INVENTION
The entry of HIV-1 into cells involves binding of the viral envelope (env) protein to CD4 followed by interaction with one of several coreceptors (reviewed in E. A. Berger, 1997,
AIDS,
11:S3-S16; Broder et al., 1997,
J. Leukocyte Biol.,
62:20-29; Doms et al., 1997,
Virology,
235:279-190; and Moore et al., 1997,
Curr. Opinion Immunol.,
9:551-562). Binding of the env protein to the appropriate coreceptor is thought to trigger conformational changes in env that mediate fusion between the viral membrane and the host cell membrane. The CCR5 and CXCR4 chemokine receptors have been identified as major HIV-1 coreceptors in that all HIV-1 strains examined to date use one or both of these molecules as second receptors. CCR5 supports infection by R5 (M-tropic) virus strains, while CXCR4 supports infection by X4 (T-tropic) virus isolates (Alkhatib et al., 1996,
Science,
272:1955-1958; Berger et al., 1998,
Nature,
391:240; Choe et al., 1996,
Cell,
85:1135-1148; Deng et al., 1996,
Nature,
381:661-666; Doranz et al., 1996,
Cell,
85:1149-1158; Dragic et al., 1996,
Nature,
381:667-673; and Feng et al., 1996,
Science,
272:872-877). R5-X4 (dual-tropic) viral env proteins can, in conjunction with CD4, use either CCR5 or CXCR4 for cellular entry. The differential utilization of CCR5 and CXCR4 by HIV strains, coupled with their expression patterns in CD4 positive cells largely explains viral tropism at the level of entry.
In addition to CCR5 and CXCR4, a number of other chemokine and orphan seven transmembrane domain receptors have been shown to function as coreceptors for one or more virus strains in vitro, including CCR2b, CCR3, CCR8, CX3CR1, GPR1, GPR 15, STRL33, US28, and ChemR23 (Choe et al., 1996,
Cell
85:1135-1148; Deng et al., 1997,
Nature
388:296-300; Doranz et al., 1996,
Cell
85:1149-1158; Farzan et al., 1997,
J. Exp. Med.
186:405-411; Liao et al., 1997,
J. Exp. Med.
195:2015-2023; Pleskoff et al., 1997,
Science
276:1874-1878; Reeves et al., 1997,
Virology
231:120-134; Rucker et al., 1997,
J. Virol.
71:8999-9007). In general, these alternative coreceptors support virus infection less efficiently than either CCR5 or CXCR4. However, use of alternative coreceptors may help explain certain facets of HIV-1 tropism and pathogenesis in vivo. For example, neurologic disease is a serious and relatively frequent consequence of HIV-1 infection, with microglia being the primary targets of virus infection in the central nervous system (Bagasra et al., 1996,
AIDS,
10:573-585; Sharer et al., 1992,
J. Neuropath. Exp. Neurol.,
51:3-11; Wiley et al., 1986,
Proc. Natl. Acad. Sci., USA,
83:7089-7093). Microglia express both CCR3 and CCR5 and it has been suggested that utilization of CCR3 by a virus strain may correlate with neurotropism (He et al., 1997,
Nature,
385:645-649).
The identification of additional coreceptors for the HIV virus would provide an important tool for investigating and controlling HIV infection.
SUMMARY OF THE INVENTION
In one aspect of the invention, the invention relates to a recombinant eukaryotic cell transformed with a polynucleotide encoding an APJ polypeptide and/or a polynucleotide encoding a CD4 polypeptide, wherein the cell coexpresses APJ and CD4 polypeptides.
The invention also relates to an antibody which specifically binds to an extracellular domain of APJ, wherein the antibody inhibits HIV infection of a target cell that coexpresses APJ and CD4 polypeptides or wherein the antibody inhibits membrane fusion between a first cell coexpressing APJ and CD4 polypeptides and a second cell expressing an HIV env protein.
The invention also relates to a substantially purified peptide fragment of APJ, wherein the peptide inhibits HIV infection of a target cell that coexpresses APJ and CD4 polypeptides or wherein the peptide inhibits cell fusion between a first cell coexpressing APJ and CD4 polypeptides and a second cell expressing an HIV env protein.
In another aspect of the invention the invention relates to methods for identifying compounds that modulate the interaction between an HIV virus and an APJ receptor.
The invention also relates to a method of inhibiting HIV infection of a target cell expressing an APJ and CD4 polypeptides comprising contacting the target cell with an effective amount of an APJ binding or blocking agent.
The invention also relates to a method of treating a subject having or at risk of having an HIV infection or related disorder, comprising administering a therapeutically effective amount of an anti-APJ antibody to the subject.
REFERENCES:
patent: 97/45543 (1997-12-01), None
Linqi Zhang et al., Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1, Journal of Virology, vol. 72, No. 11, Nov. 1998, pp. 9307-9312.
Yi-Jun Zhang et al., Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro, Journal of Virology, vol. 72, No. 11, Nov. 1998, pp. 9337-9344.
Kazuhiko Tatemoto et al., “Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor,” Biochemical and Biophysical Research Communications 251, pp. 471-476 (1998).
Trevor L. Hoffman et al.,“HIV Type I Envelope Determinants for Use of the CCR2b, CCR3, STRL33, and APJ Coreceptors,” Proc. Natl. Acad. Sci. USA, vol. 95, pp. 11360-11365, Sep. 1998.
Michael Farzan et al., “A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association Between gp120 and CCR5,” Journal of Virology, vol. 72, No. 2, Feb. 1998, p. 1160-1164.
Aimee L. Edinger et al., “An Orphan Seven-Transmembrane Domain Receptor Expressed Widley in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus,” Journal of Virology, vol. 72, No. 10, Oct. 1998, pp. 7934-7940.
Choe et al., “The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1”, J. of Virology, vol. 72, No. 7, Jul. 1998, pp. 6113-6118.
Brian F. O'Dowd et al., “A human gene that shows identity with the gene encoding the angiotensin . . . ” Gene, vol. 136, 1993, pp. 355-360.
Choe et al., “The &bgr;-Chemokine Receptors CCR3 and CCR5 . . . ” Cell, vol. 85, Jun. 28, 1996, pp. 1135-1148.
Feng et al., “HIV-2 Entry cofactor: Functional cDNA cloning of a Seven-Transmembrane . . . ”, Science, vol. 272, May 10, 1996, pp. 872-877.
Dragic et al., “HIV-1 entry into CD4+ cells is mediated . . . ”, Nature vol. 381, June 20, 1996, pp. 667-673.
Deng et al., “Identification of a major co-receptor . . . ”, Nature, vol. 381, Jun. 20, 1996, pp 661-666.
Doranz et al., “A Dual-Tropic Primary HIV-1 Isolate . . . ”, Cell, vo. 85, Jun. 28, 1996, pp. 1149-1158.
Matsumoto et al., “Low stringency hybridization study of the dopamine . . . ” Neuoroscience Letters, vol. 219, (1996), pp. 119-122.
Dohlman et al., “Model systems for the study of seven-transmembrane-segment receptors”, Annu. Rev. Biochem, 1991, vol. 60, pp. 653-688.
Kolson et al., “The Effects of human immunodeficiency virus in the central nervous system”, in Ad. in Virus Res., vol. 50, pp. 1-47, Academic Press, 1998.
Rucker et al., “Utilization of Chemokine receptors, Orphan Receptors, . . . ”, J. of Virology, vol. 71, pp. 8999-9007, Dec. 1997.
Frazan et al., “Two Orphan Seven-Transmembrane Segment receptors . . . ”, J. Exp. Med., vol. 186, No. 3, pp. 405-411, Aug. 4, 1997.
Liao et al., “STRL33, A Novel Chemokine Receptor-like Protein . . . ” J. of Exp. med., vol. 185, No. 11, pp 2015-2023, Jun. 2, 1997.
Reeves et al., “CD4-Independent Infection by HIV-2 (ROD/B): Use of the 7-Transmembrane . . . ”, Virology, vol. 231, pp. 130-134 (1997).
He et al., “CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia”, Nature, vol. 385, pp. 645-649, Feb. 1997.
Wiley et al., “Cellular localization of human immunodeficiency virus infection . . . ”, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 7089-7093, Sep. 1986.
Doms Robert W.
Faulds Daryl
Hesselgesser Joseph E.
Horuk Richard
Mitrovic Branislava
Budens Robert D.
Millen White Zelano & Branigan P.C.
Schering Aktiengesellschaft
LandOfFree
Methods and compositions for modulating the interaction... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating the interaction..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating the interaction... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2926051